Over-the-Counter (OTC) Drug Review | OTC Monograph Reform in the CARES Act
Information about Over-the-Counter (OTC) Monograph Reform
A resource for the public to view OTC Monographs and their Administrative Orders (Proposed, Final, and Interim Final). OTC Monographs@FDA also facilitates the ability for the public to submit, search, and view comments and data for Proposed and Interim Final Administrative Orders, except if otherwise specified.
Latest News
- 5/2/23: FDA posts remaining five final administrative orders as deemed by the CARES Act on OTC Monographs@FDA. FDA also posts a revision to final Administrative Order OTC000024 Over-the-Counter Monograph M001: Antacid Products for Over-the-Counter Human Use
- 4/12/23: FDA issues draft guidance for industry "Over-the-Counter Monograph Order Requests (OMORs): Format and Content"
- 3/24/23: Federal Register Notice: Over-The-Counter Monograph Drug User Fee Rates for Fiscal Year 2023
- 10/14/22: FDA posts six additional final administrative orders as deemed by the CARES Act on OTC Monographs@FDA
- 10/3/22: FDA announces expansion of CDER NextGen Portal to enable certain electronic OTC monograph submissions
- 9/27/22: FDA issues draft guidance for industry “Providing Over-the-Counter Monograph Submissions in Electronic Format”
- 4/4/22: FDA posts two additional final administrative orders as deemed by the CARES Act on OTC Monographs@FDA
- 2/1/22: FDA posts draft guidance for industry “Formal Meetings Between FDA and Sponsors or Requestors of Over-the-Counter Monograph Drugs”
About OTC Monograph Reform
On Friday, March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was signed into law to aid response efforts and ease the economic impact of COVID-19. In addition to the COVID-19 response efforts, the CARES Act includes statutory provisions that reform and modernize the way OTC monograph drugs are regulated in the United States. Specifically, the CARES Act replaces the rulemaking process with an administrative order process for issuing, revising, and amending OTC monographs. The CARES Act also provides FDA the authority to assess and collect user fees dedicated to OTC monograph drug activities. FDA anticipates that this user fee program will provide additional resources to help the agency conduct these important regulatory activities in a timely manner and ultimately help provide the public with access to innovative OTC monograph drugs. On March 26, 2021, FDA updated and reissued the rates for over-the-counter (OTC) monograph drug user fees for fiscal year (FY) 2021 in a Federal Register Notice (FRN) titled “Fee Rates under the Over-The-Counter Monograph Drug User Fee Program for Fiscal Year 2021.” On March 16, 2022, FDA announced the rates for over-the-counter (OTC) monograph drug user fees for fiscal year (FY) 2022 in a Federal Register Notice (FRN) titled “Over-The-Counter Monograph Drug User Fee Rates for Fiscal Year 2022.”
In support of the law, the Over the Counter Monograph User Fees Program Performance Goals and Procedures document was drafted to specify FDA and industry mutually agreed upon timelines. FDA has updated the dates (See Updated Over-the-Counter Monograph User Fee Program Performance Goals Dates– Fiscal Years 2021-2025) to be used for purposes of the Over-the-Counter Monograph User Fee Program Performance Goals and Procedures (OMUFA goals letter) to reflect that FY 2021 is the first program year, per the statutory authority for OMUFA fees enacted under the Coronavirus Aid, Relief, and Economic Security (CARES) Act. This updating aligns with language in the OMUFA goals letter stating that although it was drafted under the assumption that FY 2018 would be the first program year, "If the program has a different effective date, goal dates…will need to be adjusted accordingly." The updated goals dates should be referred to in place of the "Summary of Dates of Specified Activities under OMUFA" table on pages 34-37 of the OMUFA goals letter.
OTC Monographs@FDA
FDA created a new public web portal, OTC Monographs@FDA, that provides the public with the ability to view proposed and final administrative orders, as well as interim final administrative orders for OTC monograph drugs.
To access the administrative orders, go to OTC Monographs@FDA. Under the “Administrative Orders” banner, click on the desired link under the “Order ID” heading and follow the prompts.
To access the OTC Monographs, under the “OTC Monographs” banner, click on the desired link under the “OTC Monograph ID” heading and follow the prompts. OTC Monographs@FDA also facilitates the submission of comments and data from the public for proposed and interim final administrative orders.
Instructions on how to submit data, information, and public comments for proposed and interim final administrative orders will be posted in the OTC Monographs@FDA portal.
CDER NextGen Portal
FDA’s CDER NextGen Portal is a website for users to report information to FDA, including certain OTC monograph submissions. Now, sponsors and requestors of OTC monograph drugs are able to use the CDER NextGen Portal to submit requests for formal meetings with FDA and materials related to the formal meetings. In the future, sponsors and requestors will be able to submit other OTC monograph submissions via the CDER NextGen Portal, including OTC monograph order requests (OMORs), formal dispute resolution requests related to a final administrative order, administrative hearing requests related to a final administrative order, and responses to record requests by FDA relating to minor changes.
Annual Forecast
On September 30, 2022, FDA posted the second Annual Forecast for Planned Monograph Activities. The Annual Forecast is a nonbinding list, issued each year, of planned monograph activities that FDA intends to address over the upcoming three years.
More information is available in the FAQs section below.
Recent Communications
- October 3, 2022 CDER Statement: FDA Expands CDER NextGen Portal to Enable Certain Electronic Over-the-Counter (OTC) Monograph Submissions
- September 20, 2021 FDA-In-Brief: FDA Posts an Initial Batch of Four Deemed Final Administrative Orders for
- Over-the-Counter (OTC) Drugs
- March 25, 2021 FDA In Brief: FDA Republishing Fee Rates under the Over-the-Counter Monograph Drug User Fee Program
- August 6, 2020 FDA Voices: An Exciting New Chapter in OTC Drug History: OTC Monograph Reform in the CARES Act
- March 30, 2020 FDA Statement: FDA on Signing of the COVID-19 Emergency Relief Bill, Including Landmark Over-the-Counter Drug Reform and User Fee Legislation
Presentations
- “The Nonprescription Drug Facts Label in a Changing Consumer Marketplace 2021” webinar presentation from June 9, 2021.
- “OTC Monograph Reform in the CARES Act: Safety Orders” webinar presentation from January 27, 2021
- “Monograph reform is here! Learn what to expect and how to prepare” webinar presentation from May 29, 2020
Meetings
- 12/1/2022 FDA and Industry OMUFA Implementation Meeting Minutes
- 9/1/2022 FDA and Industry OMUFA Implementation Meeting Minutes
- 4/19/2022 FDA and Industry OMUFA Implementation Meeting Minutes
- 12/13/2021 FDA and Industry OMUFA Implementation Meeting Minutes
- 8/31/2021 FDA and Industry OMUFA Implementation Meeting Minutes
- 4/13/2021 FDA and Industry OMUFA Implementation Meeting Minutes
User Fees
| FY 2023 Facility User Fee Rates | |
|---|---|
| Monograph Drug Facility (MDF) Facility Fee | $26,153 |
| Contract Manufacturing Organization (CMO) Facility Fee | $17,435 |
| FY 2023 OMOR Fee Rates | |
|---|---|
| Tier 1 | $517,381 |
| Tier 2 | $103,476 |
- Information regarding Over-The-Counter Monograph User Fee Program (OMUFA)
Frequently Asked Questions, by topic
- General Information
- Administrative Orders and OTC Monograph Order Requests (OMOR)
- Deemed Final Orders
- User Fees
- Electronic Submissions
- Meetings
- Annual Forecast for Planned Monograph Activities
- Status of Existing OTC Monograph Products
General Information
An OTC monograph drug is a nonprescription, over-the-counter (or OTC) drug that may be marketed without an approved drug application under section 505 of the FD&C Act if it meets the requirements of section 505G of the FD&C Act, as well as other applicable requirements.
Simply stated, an OTC monograph is a "rule book" for each therapeutic category establishing conditions, such as active ingredients, uses (indications), doses, route of administration, labeling, and testing under which an OTC drug is generally recognized as safe and effective (GRASE).
In 1972, FDA established the Over the Counter (OTC) Drug Review to evaluate the safety and effectiveness of nonprescription, OTC drug products marketed in the United States before May 11, 1972. The OTC Drug Review established conditions under which OTC drugs were generally recognized as safe and effective (GRASE) and not misbranded. These GRASE conditions were described in OTC drug monographs for each OTC therapeutic drug class. Prior to enactment of the CARES Act, the OTC Drug Review relied on a three-phase public rulemaking process to establish monographs.
For more information on the OTC Drug Review prior to enactment of the CARES Act, see the FDA webinar titled Monograph reform is here! Learn what to expect and how to prepare.
The CARES Act, enacted on March 27, 2020, includes important reforms that modernize the way OTC monograph drugs are regulated in the United States. Specifically, the CARES Act replaces the rulemaking process with an administrative order process for issuing, revising, and amending OTC monographs. The CARES Act also provides FDA the authority to assess and collect user fees dedicated to OTC monograph drug activities. FDA anticipates that this user fee program will provide additional resources to help the agency conduct these important regulatory activities in a timely manner and ultimately help provide the public with access to innovative OTC monograph drugs.
Despite FDA’s successes in providing consumers with access to a wide variety of safe and effective OTC monograph drugs, challenges with the nearly 50-year old OTC Drug Review process became apparent. The biggest challenges of the OTC Drug Review prior to the CARES Act included:
- Burdensome, multistep rulemakings to establish or amend monographs;
- FDA lacked adequate resources to devote to rulemaking process;
- Delays in finalizing monographs;
- Limited, burdensome process for innovation (e.g., new combinations of ingredients or new dosage forms);
- Delays in responding to safety issues; and
- Challenges in keeping pace with evolving science and changing market conditions.
OTC Monograph Reform is expected to accomplish the following:
- Improve the process by replacing rulemaking with administrative orders;
- Improve efficiency, timeliness, and predictability;
- Facilitate innovation;
- Establish a process to rapidly address safety issues;
- Finalize pending monographs; and
- Provide FDA with user fees to support OTC monograph drug activities.
Are there timelines and performance goals for OTC Monograph Reform under the CARES Act?
Yes, the Over-the-Counter Monograph User Fee Program Performance Goals and Procedures document outlines the performance and procedural goals and other commitments agreed to by the agency for purposes of this user fee program. These goals apply to aspects of the over-the-counter monograph drug review program that are important for facilitating timely access to safe and effective medicines regulated under the OTC drug monograph system, and to implementing the OTC monograph policy reforms.
During the first three years of OTC Monograph Reform, essentially all effective review capacity is expected to be consumed by current external mandates, safety activities, and OTC Monograph Reform implementation and infrastructure development activities. Beginning in Years 4 and 5 (and to a limited extent in Year 3), FDA expects to have built sufficient effective review capacity to begin to have timelines and performance goals for review activities expected to be part of the steady state of a monograph review program.
FDA is committed to meeting the timelines and performance goals and to continuous improvement of its performance.
Administrative Orders and OTC Monograph Order Requests (OMOR)
The CARES Act gives FDA the authority to issue an administrative order that adds, removes or changes GRASE conditions for an OTC drug monograph.
Either industry or FDA can initiate the administrative order process. A request by industry to initiate the administrative order process is called an OTC Monograph Order Request (OMOR) and can be made by a requestor, which is defined in the CARES Act as any person or group of persons marketing, manufacturing, processing, or developing a drug.
As FDA issues each proposed or final administrative order, FDA will publish the order on FDA’s public website. Additionally, FDA will also publish a notice of availability of each proposed and final administrative order in the Federal Register.
Yes. After issuance of a proposed administrative order, there will be a public comment period. The public will receive at least 45 calendar days (and potentially longer depending on the subject of the proposed order) to submit comments on the proposed administrative order. When FDA issues the proposed order, the agency will provide Information on how the public should submit their comments and the duration of the comment period.
The procedure for FDA to initiate an administrative order can be expedited when FDA determines:
- a drug poses an imminent hazard to public health; or
- a change in the labeling of a drug, class of drugs, or combination of drugs is reasonably expected to mitigate a significant or unreasonable risk of a serious adverse event associated with use of the drug.
The term ‘‘OTC monograph order request’’ (or OMOR) is defined in section 744L(7) of the FD&C Act and refers to a request for FDA to issue an administrative order under section 505G of the FD&C Act.
There are two types of OMORs: Tier 1 and Tier 2.
As described in section 744L(8) of the FD&C Act, a Tier 1 OMOR is any request not determined to be a Tier 2 OMOR.
Examples of Tier 1 OMORs include additions of:
- A new ingredient to a monograph that already has one or more ingredients that have been found to be GRASE.
- A new indication to a monograph that already has one or more ingredients that have been found to be GRASE, and the new indication applies to one or more of the GRASE ingredients.
- New monograph therapeutic category (each ingredient proposed for the new therapeutic category will be a separate OMOR).
As described in section 744L(9) of the FD&C Act, a Tier 2 OMOR is a request for:
- Reordering of existing information in the drug facts label of an OTC monograph drug;
- Addition of information to the “Other Information” section of the drug facts label of an OTC monograph drug (subject to certain limitations);
- Modification to the “Directions for Use” section of the drug facts label of an OTC monograph drug, consistent with a minor dosage form change;
- Standardization of the concentration or dose of a specific finalized ingredient within a particular finalized monograph;
- Change to ingredient nomenclature to align with nomenclature of a standards-setting organization; or
- Addition of an interchangeable term in accordance with section 330.1 of title 21, Code of Federal Regulations (or any successor regulations).
Based on program implementation experience or other factors found appropriate by FDA, FDA may also characterize any OMOR as a Tier 2 OMOR (including recharacterizing a request from Tier 1 to Tier 2) and publish such determination in a proposed order issued pursuant to section 505G of the FD&C Act.
In April 2023, FDA issued a draft guidance for industry titled Over-the-Counter Monograph Order Requests (OMORs): Format and Content. Please refer to the draft guidance for the agency’s recommendations on the format and content of the information requestors should provide in an OMOR.
No. However, when nearing completion of the development program for an OMOR, FDA strongly encourages requestors to request a pre-OMOR submission meeting to present a summary of the data supporting the OMOR. In a pre-OMOR meeting, requestors can discuss the proposed format of the OMOR, obtain FDA feedback on the adequacy of the proposal for the OMOR submission, and discuss the appropriate categorization of the OMOR. The meeting should be sufficiently in advance of the planned submission of the OMOR to allow for a meaningful response to FDA feedback.
Section 505G(j) of the FD&C Act requires that all OTC monograph submissions, including OMORS, must be in electronic format. FDA has posted a draft guidance for industry, Providing Over-the-Counter Monograph Submissions in Electronic Format, that describes the electronic OTC monograph submissions requirement in section 505G(j) of the FD&C Act and provides recommendations and other information on how to send OTC monograph submissions to FDA in electronic format.
If you have additional questions about electronic submission of an OMOR, please contact druginfo@fda.hhs.gov.
Yes. However, while a requestor may submit an OMOR, there are currently no timelines or performance goals associated with reviewing OMORs submitted before 2024.
FDA has committed to specific timelines and performance goals in the context of OMUFA that include reviewing OMORS. These and other performance goals agreed to by FDA and industry are described in the Over-the-Counter Monograph User Fee Program Performance Goals and Procedures document, commonly referred to as the OMUFA commitment letter. Updated goal dates, accounting for the enactment date of OTC monograph reform, are available.
Deemed Final Orders
Section 505G of the Federal Food, Drug, and Cosmetic (FD&C Act), as added by the CARES Act, deemed final monographs and tentative final monographs, as described by that section, to be final orders. Among other things, section 505G describes final and tentative final monographs as being the most recently implemented version, including as modified by any proposed or final rule.
FDA ensured that the OTC monographs in the deemed final orders were appropriately harmonized, in terms of terminology and cross references (for example, since the monographs are no longer in the Code of Federal Regulations [CFR] the corresponding CFR citations and references have been updated to reflect a new order numbering system). FDA also included some other minor changes in the deemed final orders, such as consolidating professional use provisions into their own section within an OTC monograph, to provide stakeholders with more easily accessible information about the OTC monograph that is in effect for each therapeutic category.
The CARES Act established the deemed final orders, which were effective upon enactment of the CARES Act on March 27, 2020.
FDA will post the deemed final orders (DFOs) in batches on a rolling basis until all deemed final orders are available on the public-facing web portal at OTC Monographs@FDA. The initial batch of OTC monograph DFOs along with the overall process for posting the DFOs were announced in a Notice of Availability (NOA) in the Federal Register. Subsequent batches of OTC monograph DFOs will be announced on FDA’s OTC monograph webpage. As discussed in the same NOA, FDA will also subsequently be posting the deemed final order of non-monograph conditions set forth under 21 CFR 310.545 as deemed by the CARES Act.
There is not a comment period for the deemed final orders as the content of these orders was established by operation of law and the orders are deemed to be final by the CARES Act as of March 27, 2020. If you have a question about an order, please contact druginfo@fda.hhs.gov.
All administrative orders, including the deemed final orders are available in FDA’s new public facing web-portal, OTC Monographs@FDA. To access the administrative orders, go to OTC Monographs@FDA. Under the “Administrative Orders” banner, click on the desired link under the “Order ID” heading and follow the prompts.
FDA is also posting separate OTC monograph documents that contain up-to-date OTC monograph sections that incorporate the latest final administrative orders. This provides a convenient and easy reference point for stakeholders to view the current OTC monograph, especially as the administrative order process modifies existing deemed final orders. To access these OTC monograph documents, under the “OTC Monographs” banner, click on the desired link under the “OTC Monograph ID” heading and follow the prompts.
FDA intends to issue a notice to withdraw the regulations establishing final monographs in title 21 of the CFR at a later date, once all the relevant deemed final orders have been posted on FDA’s OTC Monographs@FDA web portal (i.e., 21 CFR parts 331, 332, 333, 335, 336, 338, 340, 341, 343, 344, 346, 347, 348, 349, 350, 352, 355, 357, and 358). Prior to the withdrawal of such regulations, reference the OTC monographs posted in OTC Monographs@FDA, to the extent the corresponding deemed final order has been added to the portal.
The new public facing web-portal, OTC Monographs@FDA, is an important part of the infrastructure for the new processes under OTC monograph reform and, generally, will be used instead of regulations.gov.
The CARES Act in establishing a streamlined administrative order process for OTC monographs that is intended to improve efficiency, timeliness and predictability of the OTC monograph system requires all submissions related to the administrative order process to be in electronic format and all final orders issued by FDA to be available in a public repository. In addition, the OTC Monograph User Fee Program Performance Goals and Procedures (OMUFA goals document) calls for FDA to establish a public-facing IT dashboard and IT platform for publicly displaying OTC monograph information and for receiving electronic submissions, archiving review work, and generating reports.
As a first step in implementing the new IT systems discussed in the OMUFA goals document, FDA will post the deemed final orders to the public-facing web portal, OTC Monographs@FDA, which is the “public facing IT dashboard” referenced in the OMUFA goals document. This new web portal, OTC Monographs@FDA, provides stakeholders with the ability to search for proposed and final administrative orders that add, remove or change conditions of an OTC monograph. OTC Monographs@FDA also facilitates the submission of comments and data from stakeholders for proposed administrative orders.
Initially, as we implement OTC monograph reform, a few proposed orders may also be posted on regulations.gov, in addition to OTC Monographs@FDA, due to the historical use of regulations.gov for specific therapeutic categories. Each individual proposed order and its accompanying Federal Register Notice of Availability will contain instructions on how to submit comments.
If the order incorporates material (such as an ISO standard) by reference and states that this material is available for inspection at FDA, contact druginfo@fda.hhs.gov for more information about how to inspect. Copies of a specified publication may also be available from its publisher.
For an antiperspirant drug product marketed under section 505G of the FD&C Act that demonstrates standard effectiveness (20 percent sweat reduction) or extra effectiveness (30 percent sweat reduction) over a 24-hour period, the labeling may include effectiveness claims that the product works for all day or 24 hours.
Antiperspirant drug products marketed under section 505G of the FD&C Act cannot make effectiveness claims that the product works for more than 24 hours.
OTC external analgesic drug products that are in a patch, plaster, or poultice dosage forms and conform with the provisions of section 505G(a)(3)(A) of the FD&C Act may currently be legally marketed without an approved application.
Laxative drug products containing bisacodyl and sennosides as active ingredients and conforming with the provisions of section 505G(a)(3)(A) of the FD&C Act may currently be legally marketed without an approved application.
User Fees
| FY 2023 Facility User Fee Rates | |
|---|---|
| Monograph Drug Facility (MDF) Facility Fee | $26,153 |
| Contract Manufacturing Organization (CMO) Facility Fee | $17,435 |
| FY 2023 OMOR Fee Rates | |
|---|---|
| Tier 1 | $517,381 |
| Tier 2 | $103,476 |
The facility fee will be assessed for qualifying persons who own an OTC monograph drug facility, including contract manufacturing organization facilities.
The OTC Monograph User Fee program does not assess a facility fee for human OTC drug products that are produced under an approved drug application. The Federal Register Notice issued on 3/24/23 "Over-The-Counter Monograph Drug User Fee Rates for Fiscal Year 2023" provides more information about FY 2023 facility fees.
OTC monograph drug facility fees for FY 2023 are due June 1, 2023.
The facility fee is due annually.
Under section 744L of the FD&C Act, an OTC monograph drug facility is generally defined as a foreign or domestic business or other entity that:
- is under one management, either direct or indirect, and at one geographic location or address engaged in manufacturing or processing the finished dosage form of an OTC monograph drug;
- includes a finished dosage form manufacturer facility in a contractual relationship with the sponsor of one or more OTC monograph drugs to manufacture or process such drugs; and
- does not include a business or other entity whose only manufacturing or processing activities are one or more of the following: production of clinical research supplies; testing; or placement of outer packaging on packages containing multiple products, for such purposes as creating multipacks, when each monograph drug contained within the overpackaging is already in a final packaged form prior to placement in the outer overpackaging.
As defined in section 744L of the FD&C Act, a CMO facility is an OTC monograph drug facility where neither the owner of such manufacturing facility nor any affiliate of such owner or facility sells the OTC monograph drug produced at such facility directly to wholesalers, retailers, or consumers in the United States.
Yes, a qualifying CMO facility pays a fee equal to two-thirds of the amount of the fee for a qualifying OTC monograph drug facility that is not a CMO facility.
As described in section 744M(a) of the FD&C Act, beginning with fiscal year 2021, each person that submits an OMOR is subject to an OMOR fee upon submission of the OMOR. However, a person that submits an OMOR shall not be subject to an OMOR fee if FDA finds that the OMOR seeks to change the drug facts labeling of an OTC monograph drug in a way that would add to or strengthen—
(i) a contraindication, warning, or precaution;
(ii) a statement about risk associated with misuse or abuse; or
(iii) an instruction about dosage and administration that is intended to increase the safe use of the OTC monograph drug.
Information about fee payment procedures can be found in the Federal Register Notice issued on 03/24/23, “Over-The-Counter Monograph Drug User Fee Rates for Fiscal Year 2023.”
Electronic Submissions
OTC Monograph submissions under section 505G of the FD&C Act include, but are not limited to, the following:
- OTC monograph order requests (OMORs)
- Public comments to a proposed administrative order (issued either on FDA’s initiative or at the request of one or more requestors) or interim final administrative order
- Formal meeting requests and meeting packages
- Formal dispute resolution requests related to a final administrative order
- Administrative hearing requests related to a final administrative order
- Responses to record requests by FDA relating to minor changes
- Updates to drug listing information for the drug in accordance with section 510(j) of the FD&C Act when a change is made to a drug subject to section 505G
Section 505G(j) of the FD&C Act requires that all OTC monograph submissions must be in electronic format. FDA has posted a draft guidance for industry, “Providing Over-the-Counter Monograph Submissions in Electronic Format,” that describes the electronic OTC monograph submissions requirement in section 505G(j) of the FD&C Act and provides recommendations and other information on how to send OTC monograph submissions to FDA in electronic format.
Depending on the type of submission, OTC monograph submissions should be submitted to FDA through the CDER NextGen Portal or as specified by the instructions in the OTC Monographs@FDA portal.
The OTC Monographs@FDA portal provides a resource for the public to view proposed and final administrative orders, as well as interim final administrative orders for OTC monograph drugs and facilitates the submission of comments and data from the public for proposed and interim final administrative orders. Data, information, and public comments to a proposed order or interim final order should be electronically submitted as specified by instructions in the OTC Monographs@FDA portal.
The CDER NextGen Portal, when fully functional, will be able to be used for the electronic submission of certain OTC monograph submissions, including OMORs, formal meeting requests and meeting packages, formal dispute resolution requests related to a final administrative order, administrative hearing requests related to a final administrative order, and responses to record requests by FDA relating to minor changes.
The benefits of utilizing the CDER NextGen Portal for the submission of requests for formal meetings and related meeting correspondence include:
- Efficiency: All information regarding meeting requests is stored in one place
- Timeliness: Electronic meeting requests can be delivered immediately
- Automated confirmation: Sponsors/requestors can log in, initiate a submission, and receive an automated confirmation of a submission
- Historical record: Sponsors/requestors can view all of their submissions at any time
At this time, the CDER NextGen Portal will only enable electronic OTC monograph submissions involving requests for formal meetings between FDA and sponsors or requestors of OTC monograph drugs and related meeting correspondence (e.g., meeting packages).
In the future, FDA intends to further develop the CDER NextGen Portal to enable sponsors or requestors to submit other electronic OTC monograph submissions, including OTC monograph order requests (OMORs), formal dispute resolution requests related to a final administrative order, administrative hearing requests related to a final administrative order, and responses to record requests by FDA relating to minor changes.
If you need assistance making a type of OTC monograph submission that is not currently enabled under the CDER NextGen portal, you should check the OTC Monographs@FDA portal to see whether FDA has provided instructions on how it should be submitted electronically. If FDA has not provided instructions on how a type of OTC monograph submission should be submitted, please contact CDER’s Division of Drug Information.
Submitters need to have a CDER NextGen Portal account to submit OTC monograph submissions in electronic format through the CDER NextGen Portal. For information on how to set up a CDER NextGen Portal account and other related questions, visit the FAQs section of the CDER NextGen Portal.
Yes. Please visit the CDER NextGen Portal for user guides, FAQs, and videos. For technical support, email edmsupport@fda.hhs.gov.
Sponsors electronically submitting updates to drug listing information for a drug subject to section 505G should follow the general process for providing updated listing information and instructions that be can be found on FDA’s Electronic Drug Registration and Listing System (eDRLS) web page.
Meetings
FDA issued a draft guidance titled “Formal Meetings Between FDA and Sponsors or Requestors of Over-the-Counter Monograph Drugs” regarding formal meetings between FDA and sponsors or requestors of OTC monograph drugs (hereinafter referred to as “meeting requesters”). When finalized, this guidance will specify the procedures and principles for formal meetings between FDA and meeting requesters. It will describe procedures under which meeting requesters can meet with appropriate FDA officials to obtain FDA’s advice on the studies and other information necessary to support submissions under section 505G of the FD&C Act, other matters relevant to the regulation of nonprescription drugs, and the development of new OTC monograph drugs. The guidance will also specify procedures to facilitate efficient participation in joint meetings by multiple meeting requesters and/or organizations nominated by them to represent their interests.
Sponsors and requestors of OTC monograph drugs should submit a request for a formal meeting with FDA electronically through the CDER NextGen Portal.
Annual Forecast for Planned Monograph Activities
No. The Annual Forecast is a nonbinding list of planned monograph activities; and, FDA may address other activities if/when they arise.
No, this is a nonbinding listing of items FDA intends to address.
FDA’s decision-making regarding which activities to place on the Annual Forecast is generally guided by public health priority. The order of topics in the Annual Forecast does not reflect planned chronological order of FDA actions, or order of public health importance.
We cannot comment on the content of the planned proposed orders at this time. More information regarding the potential impact of these planned proposed orders will be provided, if necessary, when the proposed orders are issued.
Status of Existing OTC Monograph Products
Before the enactment of the Coronavirus Aid, Relief, and Economic Security Act (or the “CARES Act”) on March 27, 2020, the OTC Drug Review was a rulemaking process. As part of that process, FDA issued tentative final monographs (TFMs) in proposed rules and final OTC drug monographs in final rules. The TFMs categorized active ingredients and other OTC conditions into three different categories for safety and effectiveness: Category I for conditions FDA proposed were generally recognized as safe and effective (GRASE), Category II for conditions FDA proposed were not GRASE, and Category III for conditions that had insufficient data for FDA to propose if they were GRASE. The categories are not used in final monographs. Only active ingredients and other conditions determined by FDA to be GRASE are included in final OTC drug monographs.
No. A drug that is classified in Category II for safety or effectiveness under a tentative final monograph or that is subject to a determination to be not GRASE in a proposed rule that is the most recently applicable proposal issued under part 330 of title 21 CFR is deemed a new drug under section 201(p) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), is misbranded under section 502(ee) of the FD&C Act, and is subject to the requirement to have an approved new drug application for marketing under section 505 of the FD&C Act beginning on September 23, 2020. The Secretary has not determined that it is in the interest of public health to extend the period during which any Category II drug may be marketed without such an approved new drug application (NDA).
On March 27, 2020, the President signed into law “the Coronavirus Aid, Relief, and Economic Security Act” (or the “CARES Act”). The CARES Act included statutory provisions that reform and modernize the way OTC monograph drugs are regulated. Under Section 505G(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) as added by the CARES Act,
“[a] drug that is classified as category II for safety or effectiveness under a tentative final monograph or that is subject to a determination to be not generally recognized as safe and effective in a proposed rule that is the most recently applicable proposal issued under part 330 of title 21 of the Code of Federal Regulations, shall be deemed to be a new drug under section 201(p), misbranded under 502(ee), and subject to the requirement for an approved new drug application under section 505 beginning on the day that is 180 calendar days after the date of the enactment of this section, unless, before such day, the Secretary determines that it is in the interest of public health to extend the period during which the drug may be marketed without such an approved new drug application.”
Therefore, under the CARES Act, drugs that are classified in Category II for safety or effectiveness in a TFM or determined to not be GRASE in the most recently applicable proposed rule are deemed to be new drugs and misbranded, and cannot be marketed without an approved drug application beginning on September 23, 2020. The Secretary has not determined that it is in the interest of public health to extend the period during which any Category II drug may be marketed without such an approved new drug application (NDA).
The CARES Act established deemed final orders based on final monographs and tentative final monographs for OTC therapeutic categories that, together with other applicable requirements, set forth the current requirements for marketing OTC drug products in these therapeutic categories without an approved application. The OTC monographs set forth in the deemed final orders provide a baseline of GRASE conditions for each therapeutic category that may be amended, revoked, or otherwise modified via the administrative order process. The administrative order process generally entails FDA issuing a proposed order and considering comments before issuing a final order. FDA posted these deemed final orders to provide stakeholders with a resource to view the OTC monographs that are embodied by deemed final orders in a simplified and usable format that is easily accessible.
A product that complies with the OTC monograph conditions embodied by a deemed final order and other applicable requirements, including general requirements for OTC drugs, can be legally marketed without an FDA approved application.
Contact Us
For questions on:
- OTC Monograph Reform druginfo@fda.hhs.gov
- User fees CDERCollections@fda.hhs.gov
- Meeting requests monograph-meeting-requests@fda.hhs.gov
- Small business and industry assistance cdersbia@fda.hhs.gov